ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CLOX | 25.61 | 0.03 | +0.12% |
| Eldridge AAA CLO ETF (CLOX) | |||
| BTCI | 33.65 | -0.22 | -0.65% |
| NEOS Bitcoin High Income ETF (BTCI) | |||
| MMMA | 23.80 | -0.16 | -0.65% |
| NYLIM MacKay Muni Allocation ETF (MMMA) | |||
| DALI | 28.53 | -0.23 | -0.78% |
| First Trust Dorsey Wright DALI Equity ETF (DALI) | |||
| DVSP | 29.68 | -0.47 | -1.54% |
| WEBs SPY Defined Volatility ETF (DVSP) | |||
A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VCYT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To ADMA | 1D Price Change % | ||
|---|---|---|---|---|
| ADMA | 100% | +7.89% | ||
| VCYT - ADMA | 36% Loosely correlated | -0.44% | ||
| ENGN - ADMA | 35% Loosely correlated | +0.51% | ||
| MAZE - ADMA | 35% Loosely correlated | +3.07% | ||
| AMRN - ADMA | 34% Loosely correlated | +0.38% | ||
| TAOX - ADMA | 33% Loosely correlated | -1.81% | ||
More | ||||
The RSI Oscillator for ADMA moved out of oversold territory on September 16, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 20 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on ADMA as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on September 22, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.
ADMA moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ADMA crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 241 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ADMA broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ADMA entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.147) is normal, around the industry mean (26.424). P/E Ratio (13.407) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.